The number of drugs in development…
The number of drugs in development has fallen for the [...]
After a career-long tenure at…
After a career-long tenure at Bayer, Nelson Ambrogio has climbed [...]
Ferring Pharmaceuticals is halting…
Ferring Pharmaceuticals is halting work on two trials of a [...]
Immunovant’s first-generation…
Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 [...]
Alto Neurosciences is halting work…
Alto Neurosciences is halting work on its schizophrenia prospect after [...]
After the FDA placed two of its…
After the FDA placed two of its next-gen HIV drugs [...]
Stipple Bio is connecting the dots…
Stipple Bio is connecting the dots toward multiple early-stage clinical [...]
After emerging from stealth last…
After emerging from stealth last month with $175 million in [...]
Oric Pharmaceuticals has picked…
Oric Pharmaceuticals has picked the phase 3 dose for its [...]
Have we passed the peak of biotech…
Have we passed the peak of biotech layoffs? It’s too [...]